Doxazosin Tablet
Product Images NDC 82804-087

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 82804-087). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-087-30 (Doxazosin 4mg 100)

82804-087-30 (Doxazosin 4mg 100)
Label for Doxazosin 4 mg oral tablets by Proficient Rx LP. Contains 30 tablets per package, each with doxazosin mesylate equivalent to 4 mg doxazosin. Tablets described as white to off-white, capsule shaped, scored, imprinted with "APO" and "095". Manufactured by Apotex Inc., Toronto, Ontario, Canada. Storage instructions included.*
FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

Doxazosin-structure.jpg (Doxazosin Structure)
Chemical structure diagram of doxazosin, showing its molecular components including a quinazoline core, piperazine ring, and methoxyphenyl group, consistent with the active ingredient doxazosin.*
FDA Label Image

Figure1.jpg (Figure1)

Figure1.jpg (Figure1)
Two line graphs showing clinical data comparing Doxazosin and placebo. The first graph depicts mean change in total symptom score from baseline over 14 weeks, with Doxazosin showing a larger decrease compared to placebo. The second graph shows mean increase in maximum urinary flow rate (mL/sec) from baseline over 14 weeks, with Doxazosin demonstrating greater improvement than placebo.*
FDA Label Image

Table3.jpg (Table3)

Table3.jpg (Table3)
Data table summarizes effectiveness from placebo-controlled trials of Doxazosin, showing symptom score and maximum flow rate changes compared to baseline. Results are provided for different dosages and studies, alongside a bar graph illustrating symptom score and maximum flow rate changes for placebo and Doxazosin 4 mg and 8 mg doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.